Daily Alpha · Reddit
· Premarket Alpha · by Buzzberg Research
Reddit split on CoreWeave and on memory names, while the most specific posts covered Elice's 30-32% IPO drop, a $42 fair value on Robinhood and copper tariffs.
Themes on this desk
CoreWeave positioning
Commenters split on CoreWeave: one is short from $60 and expects to be squeezed out around $65-70, another holds Oct. 30 $50 puts, and another bought at $81.
Memory names split
One commenter called the after-hours drop in SNDK and MU an overreaction, another holds SanDisk and Micron puts, and a third called low forward P/E on memory names a value trap after their run-ups.
Highest engagement
by score · day changeKorean GPU-rental IPO Elice fell about 30-32% on its debut
The post reports South Korean GPU-rental IPO Elice falling about 30-32% on debut amid weakness in neoclouds and Korean tech stocks.
Another Day, Another Data Center Faceplant:
The post ties the debut to weakness in neoclouds and Korean tech stocks.
Source →A reverse-DCF post put Robinhood's fair value near $42 against a $96 price
The author's DCF and reverse-DCF work puts HOOD's fair value at about $42, and the author is not convinced it is a good long-term buy at $96.
HOOD Seems super overvalued Hi All, I did a deep dive into HOOD stock.
The author would need a pullback or a new proven growth driver to buy.
Source →An ASX_Bets post argued copper tariffs and US stockpiling could keep copper tight
The author argues copper tariffs and US stockpiling could keep copper tight and help ASX miners, naming A1M as the ticker.
The Copper Bet Trump can swing copper a lot over the next 6-12 months.
The author flags tariff repeal as the downside risk.
Source →A ValueInvesting post argued data-center stocks are re-rating as pre-IPO firms are repriced or pulled
The author argues listed peers' valuations rest on committed or estimated backlog that needs more capital.
The real reason data center stock are crashing Seriously? No one is following those pre IPO data center?
The author ties the sector's lower valuations to pre-IPO data-center firms being repriced or pulled.
Source →A five-measure macro post argued an inflationary boom favors real assets over Treasuries
The author uses five frameworks to argue U.S. equities are expensive and inflation is sticky, so an inflationary boom favors real assets over nominal Treasuries.
Reading today’s macro environment with 5 measures, and how I’d position my portfolio Stocks (especially AI infra) have pulled back
The author flags conditional risks around AI credit and an oil-driven bust.
Source →Most argued
by comments per upvoteAn NVDA_Stock post said consensus estimates rose 100-200% in 13 months while the stock rose 20%
The author argues NVDA's consensus estimates have risen far more than the stock price and lists capital return, robotics, order book, share gains and software licensing as reasons it could reach $500 by the end of 2027.
In 13 months, consensus is up 100-200%, but stock only up 20% Interesting pod (Source:
The author's case rests on estimates rising faster than the share price.
Source →A WallStreetBets commenter saw 3-5x growth potential in AAOI but still picked LITE
The author said hitting guidance implies 3-5x growth next year for AAOI with LITE-like revenue at one-sixth the market cap, but named LITE as the single pick.
Yes agree. But I like AAOI because if they hit their guidance then they are 3-5xing next year.
The comparison rests on AAOI hitting its guidance.
Source →A WallStreetBets poster argued Take-Two is not priced for GTA 6
The author argues Take-Two is not priced in for GTA 6 and says they are buying and will continue to buy.
TTWO will explode Everyone is saying priced in. Not true. People have no idea.
The thesis rests on the GTA 6 release not being reflected in the share price.
Source →A biotech post expects Lenz Therapeutics to report a strong third quarter on VIZZ demand
The author expects Lenz Therapeutics to report a strong Q3 driven by improved VIZZ demand, a new telehealth channel, rising prescriptions and search interest.
What do you expect from the Q3?
The call rests on VIZZ demand improving.
Watch Lenz Therapeutics' third-quarter report.
Source →